Paloma Partners’s Viking Therapeutics VKTX Stock Holding History

Paloma Partners’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-71,266	Closed	-$3.78M	–	1706
2024 Q2	$3.78M	Buy	+71,266	New	+$4.67M	0.11%	193

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Paloma Partners's VKTX Position: Q3 2024 in Review

Paloma Partners sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 71,266 shares — an estimated $3.78M sold.

Paloma Partners first reported a position in VKTX in Q2 2024 and held it in 1 quarter. The position peaked at $3.78M in Q2 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

Paloma Partners reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
Paloma Partners sold 71,266 Viking Therapeutics shares in Q3 2024, an estimated $3.78M.
Paloma Partners first reported a position in Viking Therapeutics in Q2 2024 and held it in 1 quarter.
Paloma Partners's Viking Therapeutics position peaked at $3.78M in Q2 2024.
422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.